Clinical Report: Fluvoxamine Reduces Long COVID Fatigue in Trial
Overview
Fluvoxamine significantly reduced fatigue severity in patients with long COVID compared to placebo, while metformin showed no benefit. The findings suggest fluvoxamine may improve quality of life and warrant further investigation.
Background
Long COVID, affecting millions globally, presents persistent symptoms that significantly impact patients' quality of life. Effective treatments are urgently needed as current clinical guidelines focus on supportive care without specific pharmacotherapies for fatigue. This trial explores fluvoxamine's potential as a therapeutic option for managing long COVID-related fatigue.
Data Highlights
| Outcome | Fluvoxamine | Placebo | Metformin |
|---|---|---|---|
| Fatigue Severity Scale Score Change (Day 60) | Significant Reduction | No Change | No Benefit |
| Recovery (FSS score < 3) | More Frequent | Less Frequent | No Consistent Benefit |
| Adverse Events | 20% | 30% | 29% |
Key Findings
- Fluvoxamine reduced fatigue scores compared to placebo at days 60 and 90.
- Metformin did not demonstrate any significant improvement in fatigue severity.
- Recovery from fatigue was more common in the fluvoxamine group across all time points evaluated.
- Fluvoxamine improved health-related quality of life at days 30, 60, and 90.
- Adverse events were reported in 20% of fluvoxamine patients, lower than metformin and placebo groups.
- Subgroup analyses indicated consistent benefits of fluvoxamine across various demographics.
Clinical Implications
The results suggest that fluvoxamine may be a viable treatment option for managing fatigue in long COVID patients, potentially improving their quality of life. Clinicians should consider fluvoxamine in treatment plans while remaining aware of the need for further research to confirm these findings.
Conclusion
Fluvoxamine shows promise in reducing fatigue and enhancing quality of life for patients with long COVID, highlighting the need for additional studies to validate these results and explore the underlying mechanisms.
Related Resources & Content
- Author(s)/Org, Annals of Internal Medicine, 2026 -- Fluvoxamine Reduces Long COVID Fatigue in Trial
- Infection — Links Between Selective Serotonin Reuptake Inhibitors and Long COVID Incidence in Depressed Patients: A Retrospective Cohort Analysis
- Open Forum Infectious Diseases — Exploring Patient-Reported Outcome Patterns in Long COVID: Insights from the STOP-PASC Clinical Trial
- The ASCO Post — Study Finds Up to 15% of Patients With Cancer Experience 'Long Haul' COVID-19 KEY POINTS
- Long COVID Clinical Guidance | Long COVID | CDC
- Antidepressant relieves fatigue in people with long COVID, study finds | CIDRAP
- Drugs - Real World Outcomes — Long-Term Post-Marketing Evaluation of Fluvoxamine Maleate in Japanese Patients with Social Anxiety Disorder
- Long COVID Clinical Guidance | Long COVID | CDC
- Antidepressant relieves fatigue in people with long COVID, study finds | CIDRAP
- Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial | Trials | JAMA | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
